Novartis Korea breaks 200 billion won in 2006 salses

In just three years, Novartis Korea pushed up its annual sales by a whopping a 200 billion won level backed by robust business growth of its flagship products, including Diovan, a highly selective angiotensin II receptor blocker (ARB).

Last year, Novartis Korea chalked up 182.3 billion won in sales, up 25.4 percent from 145.4 billion won in 2005.

Together with Exjade (chronic iron overloa...